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Abstract
Background: Albumin is the most abundant protein in blood plasma, and due to its ligand binding
properties, serves as a circulating depot for endogenous and exogenous (e.g. drugs) compounds.
Hence, the unbound drug is the pharmacologically active drug. Commercial human albumin
preparations are frequently used during surgery and in critically ill patients. Recent studies have
indicated that the use of pharmaceutical-grade albumin is controversial in critically ill patients. In
this in vitro study we investigated the drug binding properties of pharmaceutical-grade albumins
(Baxter/Immuno, Octapharma, and Pharmacia & Upjohn), native human serum, and commercially
available human serum albumin from Sigma Chemical Company.
Methods: The binding properties of the various albumin solutions were tested in vitro by means of
ultrafiltration. Naproxen, warfarin, and digitoxin were used as ligands. HPLC was used to quantitate
the total and free drug concentrations. The data were fitted to a model of two classes of binding
sites for naproxen and warfarin and one class for digitoxin, using Microsoft Excel and Graphpad
Prism.
Results: The drugs were highly bound to albumin (95–99.5%). The highest affinity (lowest K1) was
found with naproxen. Pharmaceutical-grade albumin solutions displayed significantly lower drug-
binding capacity compared to native human serum and Sigma albumin. Thus, the free fraction was
considerably higher, approximately 40 times for naproxen and 5 and 2 times for warfarin and
digitoxin, respectively. The stabilisers caprylic acid and N-acetyl-DL-tryptophan used in the
manufacturing procedure seem to be of importance. Adding the stabilisers to human serum and
Sigma albumin reduced the binding affinity whereas charcoal treatment of the pharmaceutical-grade
albumin from Octapharma almost restored the specific binding capacity.
Conclusion: This in vitro study demonstrates that the specific binding for warfarin and digitoxin is
significantly reduced and for naproxen no longer detectable in pharmaceutical-grade albumin. It
further shows that the addition of stabilisers may be of major importance for this effect.
Published: 29 March 2004
BMC Clinical Pharmacology 2004, 4:4
Received: 23 December 2003
Accepted: 29 March 2004
This article is available from: http://www.biomedcentral.com/1472-6904/4/4
© 2004 Olsen et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/4
Page 2 of 9
(page number not for citation purposes)
Background
Albumin is the most abundant protein in blood plasma.
One of its main functions is transporting endogenous and
exogenous compounds, which might be toxic in the
unbound state, but non-toxic as albumin-bound. Thus the
albumin may serve as a circulating depot, whereas the
unbound substances are the pharmacologically active
moieties [1,2]. Changes in the free drug concentration due
to displacement or pathological states like impaired renal
or liver function and hypoalbuminaemia may increase
drug effect, particularly if the drug is highly albumin-
bound [3]. Albumin also plays an essential role in gener-
ating the colloid osmotic pressure, and has a long history
of clinical use in colloid replacement therapy. The
Cochrane injuries group albumin reviewers [4] reported a
possible excess mortality after albumin administration in
critically ill patients. Some mechanisms behind the harm-
ful effect were discussed, but altered binding properties of
albumin were not mentioned.
Recently, another meta-analysis by Wilkes and Navickis
[5] was not able to detect any effect of albumin adminis-
tration on mortality. Thus, the use of albumin in critically
ill patients is controversial. Børmer et al. [6] reported that
an albumin assay (Vitros "dry chemistry" bromocresol
green (BCG) albumin method) underestimated the albu-
min concentration in pharmaceutical-grade albumin
from Baxter/Immuno, Octapharma, and Pharmacia &
Upjohn, compared to serum protein electrophoresis
(SPE) and a manual BCG method. This was the case also
with serum samples from patients receiving significant
amounts of albumin. Due to the findings [4-6] we wanted
to study the drug-binding properties of pharmaceutical-
grade albumins, native sera from healthy volunteers, and
defatted albumin from Sigma (commercially available
and without the stabilisers caprylic acid and N-acetyl-DL-
tryptophan).
Naproxen, warfarin, and digitoxin were selected as test
drugs. According to Sudlow et al. [7] and Sjøholm et al.
[8], these drugs represent three different binding sites on
the albumin molecule and all are highly albumin-bound,
i.e. more than 95 % bound. During the manufacturing
process of pharmaceutical-grade albumin (Cohn) the sta-
bilisers caprylic acid (octanoic acid) and N-acetyl-DL-
tryptophan are added before pasteurisation. Thus we also
studied the effects of the stabilisers caprylic acid and N-
acetyl-DL-tryptophan on drug binding by adding the sta-
bilisers to stabiliser-free albumin solutions and by char-
coal purification of pharmaceutical-grade albumin.
Methods
Chemicals and reagents
Tris-base, phosphate buffered saline (PBS) (D-5773),
naproxen (M-4015), warfarin (A-2250), digitoxin (D-
5878) and defatted human serum albumin (A-3782) were
purchased from Sigma Chemical Co., St. Louis, MO, USA.
HPLC grade methanol and acetonitrile were from Merck,
Darmstadt, Germany. N,N-Dimethyloctylamine (DMOA)
was from Aldrich, St. Louis, MO, USA. Sodium caprylate
and N-acetyl-DL-tryptophan were from ICN Biomedicals
Inc., Ohio, USA. Pharmaceutical-grade albumin (200 g/L)
was purchased from Baxter/Immuno, Octapharma, and
Pharmacia & Upjohn. From Octapharma we also received
an in-process albumin concentrate, collected just before
the addition of stabilisers and final heating (in-process
albumin). Human serum was obtained from five healthy
volunteers (4 females, 1 male), age 25–42 years. All aque-
ous reagents were made up in water purified through a
Milli-Q UF-PLUS system (Millipore Corp., Bedford, MA,
USA).
Stock solutions and standards
Stock solutions of naproxen (0.1 mol/L) and of warfarin
(0.1 mol/L) were prepared in 0.110 mol/L NaOH. Stock
solutions of digitoxin (0.01 mol/L) were prepared in eth-
anol. These stock solutions were stored in glass vials at
+4°C, and new dilutions for HPLC calibrations or binding
experiments were prepared each day in the appropriate
matrix. PBS was prepared in purified water and pH
adjusted to 7.35 with HCl, then filtered through a 0.22
µm filter into a sterilised container and pH controlled to
be 7.40.
Experimental design
The albumin concentrations of the human sera used in
the experiments were 0.606 (±0.023) mmol/L (39.4 g/L).
Pharmaceutical-grade albumin concentrates (200 g/L)
and Sigma albumin were diluted with PBS to 0.615
mmol/L (40 g/L). Both human serum and the albumin
solutions were adjusted to pH 7.40 with H3PO4  and
NaOH respectively, filtered (0.22 µm filter), stored in
aliquots (11 mL) and frozen at -70°C [9]. Before use the
solutions were thawed and heated to +37°C in a water
bath before final pH-control. The albumin solutions were
divided into 10 separate samples of 1 ml each before addi-
tion of 10 different drug concentrations. After drug admix-
ture albumin samples were pipetted into pre-heated
Amicon Centrifree filter units. Duplicates of 10 µL were
removed for determination of total drug concentration.
To produce ultrafiltrates with unbound drug, the samples
were equilibrated on the Amicon Centrifree filters (mem-
brane pore size 30 000 molecular weight cut-off) at
+37°C in a hot-air oven for 30 minutes prior to centrifu-
gation. Centrifugations were done at +37°C, albumin
solutions for 5 min at 1 000 × g and human serum for 10
min at 1 640 × g according to the method of Borgå &
Borgå [9], resulting in filtrate volumes of 0.25–0.33 mL.
The pH of the solution was controlled before and afterBMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/4
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ultrafiltration without finding any significant effects, as
stated by Borgå & Borgå [9].
Each experiment with one matrix included ten drug con-
centrations covering a broad concentration range. The
total drug concentrations (mmol/L) tested were:
naproxen 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.5, 2.0; war-
farin 0.05, 0.1, 0.2, 0.3, 0.4, 0.6, 1.0, 1.5, 2.0, 2.5; digi-
toxin 0.02, 0.03, 0.04, 0.05, 0.1, 0.2, 0.25, 0.30, 0.35,
0.40. In separate experiments when specific binding was
investigated, the 5 lowest concentrations of naproxen and
warfarin were used. The isolated effects of the stabilisers
caprylic acid and N-acetyl-DL-tryptophan, on binding
capacity of naproxen, warfarin, and digitoxin were inves-
tigated by adding the stabilisers to Sigma albumin solu-
tions and human serum and by charcoal treatment of the
pharmaceutical-grade and an in-process albumin solution
from Octapharma.
Analyses
Albumin concentrations were measured immunoneph-
elometrically on a Beckman Immage Immunochemistry
System (Beckman Instruments) [6]. The unbound (free)
and total drug concentrations in solutions were deter-
mined by reversed phase High Performance Liquid Chro-
matography (HPLC). For naproxen, according to Borgå &
Borgå [9] with some modifications: In brief, the mobile
phase was a 25 mmol/L potassium phosphate buffer pH
2.50 (62.5+37.5 acetonitrile), the column used was a
Purospher Star RP-18e, 55 × 4 mm with 3 µm particles
(Merck, Darmstadt, Germany), and naproxen was
detected by native fluorescence [10]. Warfarin was quanti-
fied with a modified version of the method described by
Wong et al. [11]: The mobile phase was a 25 mmol/L Tris-
HCl buffer pH 7 (65+35 acetonitrile) with the ion-pairing
agent DMOA added to the buffer/acetonitrile mixture to a
final concentration of 10 mmol/L.
The addition of DMOA raised the pH of the mobile phase
to approximately 8.5, sufficiently high to be able to detect
warfarin by native fluorescence. The column used for sep-
aration was a Purospher Star RP-18e, 55 × 4 mm with 3
µm particles. Digitoxin was separated and detected as
described by Plum et al. [12] with minor modifications.
Sample preparation was adapted from Dasgupta et al. [13]
and the procedure for the Abbot TDx Digitoxin assay.
Determination of tryptophan, N-acetyl-DL-tryptophan,
and the internal standard N-formyl-DL-tryptophan were
performed using perchloric acid to precipitate proteins
before separation on a C-8 column using octanesulfonic
acid as ion-pairing agent. The compounds of interest were
detected by native fluorescence [14-16].
Apparatus, chromatography
Chromatographic equipments were from Shimadzu
Corp., Tokyo, Japan. The solvent delivery system con-
sisted of a DGU-3A on-line degasser coupled to a LC-9A
quartenary gradient pump. Column temperature was
maintained using a CTO-6A column oven and on-line sol-
vent preheater. Samples were injected with a SIL-9A
autoinjector. Digitoxin was detected by an SPD-6AV vari-
able wavelength detector, N-acetyl-DL-tryptophan, warfa-
rin, and naproxen were detected by a RF-551 fluorescence
detector. Data acquisition and integration were per-
formed by a Class-VP 4.2 computer-based integration
system.
Data treatment
The free fraction (fraction of unbound drug) was calcu-
lated as the ratio of the ultrafiltrate (free) concentration
and the total concentration determined in the HPLC anal-
ysis. The drug concentrations were plotted according to
Scatchard [17] where the abscissa represents the binding r
(the number of molecules of drug bound per molecule of
albumin), and the ordinate r/x (x = free drug concentra-
tion). The data of r and x were fitted by linear least squares
regression analysis when number of binding sites (n1 and
n2) and dissociation constants (K1 and K2) for high (n1
and K1) and low (n2 and K2) affinity binding were calcu-
lated. The drug concentrations representing the specific
binding range were additionally evaluated in a double
reciprocal plot of r and x according to Lineweaver-Burk
[18]. Results given are means (SDs) of three to five sepa-
rate experiments. Microsoft Excel and GraphPad Prism
were used for calculating the results. Wilcoxon's signed
rank test was used for statistical analysis.
Table 1: Percentage unbound (free) drug concentrations of naproxen, warfarin, and digitoxin in various albumin solutions
Naproxen 0.1 mmol/L Warfarin 0.05 mmol/L Digitoxin 0.02 mmol/L
Human serum 0.07 (0.02)% 0.7 (0.2)% 4.9 (0.2)%
Sigma albumin 0.04 (0.01)% 1.1 (0.2)% 5.1 (0.4)%
Baxter/Immuno 2.77 (0.09)%* 4.1 (0.2)%* 11.1 (0.3)%*
Pharmacia & Upjohn 3.15 (0.17)%* 5.2 (0.5)%* 11.5 (0.4)%*
Octapharma 2.61 (0.10)%* 4.8 (0.3)%* 10.0 (0.4)%*
Percent free drug concentrations of naproxen, warfarin, and digitoxin calculated from the results obtained by ultrafiltration of the albumin solutions 
and human serum. The solutions were diluted to the final albumin concentration of 0.615 mmol/L. Values are means (SDs) of five separate 
experiments. * p < 0.05 compared with Sigma albumin and human serum.BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/4
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Results
Naproxen, warfarin, and digitoxin were highly bound in
solutions of Sigma albumin and native human serum,
yielding free fractions of approximately 0.05, 1.0, and 5%
respectively (Table 1). The free fractions were considera-
bly higher in albumin solutions from Baxter/Immuno,
Octapharma, and Pharmacia & Upjohn, approximately
40-times for naproxen and 5 and 2 times for warfarin and
digitoxin (Table 1). In figure 1 the results of the binding
studies with various concentrations of naproxen (fig 1a),
warfarin (fig 1b), and digitoxin (fig 1c) in different albu-
min solutions, plotted according to Scatchard [17], are
shown. In native human serum and Sigma albumin, the
binding of naproxen and warfarin yielded a biphasic
curve with approximately one specific albumin binding
site (n1) each, while the number of unspecific binding
sites (n2) ranged from 3 to 5. Digitoxin displayed a
straight line, indicating specific binding only, as intended
at the concentrations selected. Naproxen elicited the high-
est affinity with the lowest dissociation constant (K1)
approximately 0.1–0.4 µmol/L. The K1 of warfarin and
digitoxin were approximately 10 and 100 times higher
(Table 2). In albumin solutions from Baxter/Immuno,
Octapharma, and Pharmacia & Upjohn, the specific bind-
ing of naproxen was abolished. Both n1 and K1 increased
to the levels of n2 and K2 (Table 2 and 3). The correlation
coefficients (r2) of the Scatchard plots (all 10 drug concen-
trations of naproxen) representing the binding of albu-
min in the products from Baxter/Immuno, Octapharma,
and Pharmacia & Upjohn were 0.99, 0.99, and 0.99
respectively. Thus the high-affinity binding site for
naproxen in pharmaceutical-grade albumin was no longer
detectable with the methods we have used. For warfarin
and digitoxin the binding was reduced without changes in
the number of binding sites, but decreasing affinity (K1
increased). Table 2 summarises the binding parameters
obtained. Non-linear regression analysis was performed
to verify the results obtained in the Scatchardanalysis, giv-
ing almost identical results (data not shown). Figure 2
shows the results of the binding studies with naproxen
(fig 2a), warfarin (fig 2b), and digitoxin (fig 2c), in con-
centrations representing the specific binding presented in
a double reciprocal plot (of r and x) according to
Lineweaver-Burk [18]. As can be seen, the y-axis intercepts
were similar with the various ligands while the x-axis
intercepts varied. When caprylic acid and N-acetyl-DL-
tryptophan (stabilisers used in preparing pharmaceutical-
grade albumin) were added to solutions of native human
serum and Sigma albumin (Table 3) to the final concen-
trations of 3.3 and 3.2 mmol/L respectively, the binding
characteristics of naproxen, warfarin, and digitoxin were
similar to that found in pharmaceutical-grade albumin
solutions (Table 2). Charcoal treatment of the in-process
albumin solution from Octapharma, without stabilisers
and not subjected to pasteurisation (Table 4), with similar
binding properties as human sera and Sigma albumin
(Table 2 and 3), decreased/impaired the albumin binding
capacity of naproxen (K1 increased from 0.1 ± 0.01 µmol/
L to 0.2 ± 0.02 µmol/L, p < 0.05) whereas the warfarin and
digitoxin binding were unaffected (Table 4). Charcoal
treatment of the pharmaceutical-grade albumin from
Octapharma restored the binding capacity of naproxen to
the level obtained with charcoal treated in-process albu-
min, without stabilisers and pasteurisation. The dissocia-
tion constant K1, and the number of binding sites n1
decreased from 75.5 ± 3.9 µmol/L and 5.7 ± 0.3 to 0.2 ±
0.02 µmol/L and 1.1 ± 0.1 (n = 5, p < 0.05, Table 4).
Discussion
Several mechanisms may lead to an increase in free frac-
tion of drugs or other ligands. Hypoalbuminaemia is
characterised by a reduction in the quantity of binding
protein available, and when this decreases, so does the
amount of bound drug [3,19]. Competitive and non-com-
petitive displacement of other ligands is another mecha-
nism to explain increased free fraction of ligands. Kragh-
Hansen [20] studied possible competitive binding
between L-tryptophan, octanoate, and diazepam. During
simultaneous presence of L-tryptophan and octanoate or
diazepam plus octanoate, pronounced mutual reductions
in binding were observed. Lagrange et al. [21] studied
binding of ketoprofen enantiomers in various human
albumin preparations. The effects of hippuric acid (in
concentrations found in uraemic patients) and octanoic
acid (one of the stabilisers used in pharmaceutical-grade
albumin) on binding characteristics of ketoprofen enanti-
omers were tested. Both hippuric and octanoic acid
induced a significant increase in the free fraction of keto-
profen enantiomers, most pronounced with octanoic
acid. Alterations in albumin binding may significantly
change pharmacokinetics and pharmacodynamics, espe-
cially for highly albumin-bound drugs. Pharmaceutical-
grade albumin is obtained from blood or plasma from
healthy human donors by fractionation according to the
cold Cohn ethanol process [22]. Stabilisers (N-acetyl-DL-
tryptophan and Na-caprylate) are then added before pas-
teurisation for 10 h at 60°C to inactivate among others
human immunodeficiency and hepatitis virus.
We have used the ultrafiltration technique in this study,
mainly due to the simple and rapid technique [23].
According to Borgå & Borgå [9], using the acidification
procedure with phosphoric acid allows CO2 to escape
prior to the ultrafiltration, keeping the pH constant dur-
ing the experiments. The binding parameters like number
of binding sites and dissociation constants (=the inverse
value of the association constant) for the ligands (Table 1,
2 and 3) are quite similar and in agreement with values
reported by others [9,19,24,25]. The present study dem-
onstrates that the specific binding of warfarin andBMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/4
Page 5 of 9
(page number not for citation purposes)
Scatchard plots of naproxen (a), warfarin (b), and digitoxin (c) binding in various albumin solutions Figure 1
Scatchard plots of naproxen (a), warfarin (b), and digitoxin (c) binding in various albumin solutions Scatchard 
plots of naproxen (a), warfarin (b), and digitoxin (c) binding in native human serum, defatted human albumin from Sigma, and 
three pharmaceutical-grade solutions from Baxter/Immuno, Octapharma, and Pharmacia & Upjohn. The symbols are given in 
separate box. The albumin solutions contained 0.615 mmol/L albumin. The experiments were performed with ultrafiltration 
and the results of the calculated parameters are found in table 2.
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digitoxin is significantly reduced and for naproxen abol-
ished in pharmaceutical-grade albumin from Baxter/
Immuno, Octapharma, and Pharmacia & Upjohn. Fur-
thermore, our study shows that caprylic acid and N-acetyl-
DL-tryptophan may be of major importance in affecting
the binding properties. It has previously been shown that
both caprylic acid and tryptophan are highly bound to
albumin [20] and that the specific binding site of these
substances is on site II, according to Sudlow et al. [7], the
binding site for naproxen. The finding (fig 2) that the
intercepts on the y-axis were almost identical whereas the
intercepts on the x-axis were quite different strongly indi-
cates a competition mechanism. The molar concentra-
tions of caprylic acid and N-acetyl-DL-tryptophan used to
stabilise albumin during the pasteurisation process are
several times higher than the albumin concentration. In
our study, binding parameters like number of binding
sites and dissociation constants obtained for the specific
binding of naproxen was no longer detectable in pharma-
Table 2: Binding parameters of naproxen, warfarin, and digitoxin in various albumin solutions
Specific binding Non Specific binding
n1 K1 (µmol/L) n2 K2 (µmol/L)
Napr. Warf. Dig. Napr. Warf. Dig. Napr. Warf. Napr. Warf.
Human serum 1.0 (0.1) 1.1 (0.1) 1.8 (0.5) 0.4 (0.4) 5.1 (1.9) 56.5 (21.0) 3.9 (0.2) 3.7 (0.1) 11.3 (0.8) 72.1 (8.2)
Sigma albumin 0.8 (0.1) 0.9 (0.1) 1.0 (0.1) 0.2 (0.1) 6.3 (1.3) 30.0 (2.2) 3.2 (0.2) 3.9 (0.3) 16.3 (1.9) 173.5 (31.2)
Baxter/Immuno 3.3* (0.6) 1.0 (0.1) 1.1 (0.1) 55.2* (10.9) 25.4* (2.4) 79.2# (6.9) 3.8 (0.2) 3.6 (0.2) 70.5* (2.0) 316.3* (27.4)
Pharmacia & Upjohn 3.5* (1.3) 1.2 (0.1) 1.4 (0.3) 66.9* (28.2) 37.6* (6.4) 113.0# (33.7) 3.8 (0.3) 3.8 (0.3) 78.5* (9.2) 342.1* (45.4)
Octapharma 4.5* (0.8) 1.3 (0.2) 0.9 (0.03) 70.0* (14.0) 39.6* (7.6) 61.2# (3.1) 4.0 (0.3) 3.9 (0.2) 60.2* (8.4) 321.1* (42.0)
The binding studies with naproxen, warfarin, and digitoxin were performed with ultrafiltration of the various albumin solutions containing 0.615 
mmol/L albumin. The binding parameters: binding sites, specific (n1) and non-specific (n2) and dissociation constants K1 and K2 were calculated 
according to Scatchard [17]. The values are means (SDs) of five separate experiments. * p < 0.05 compared with human serum and Sigma albumin. 
# p < 0.05 compared with Sigma albumin.
Table 3: Effects of caprylate and/or N-acetyl-DL-tryptophan on naproxen, warfarin, and digitoxin binding
n1 K1 (µmol/L)
No C T C+T No C T C+T
Naproxen (n = 5)
Native serum 1.0 (0.1) 5.7* (1.4) 2.6* (0.4) 3.2* (0.6) 0.5 (0.1) 67.9* (19.3) 10.4* (2.1) 49.9* (7.6)
Sigma albumin 0.8 (0.04) 2.4* (0.6) 1.4* (0.1) 2.1* (0.4) 0.1 (0.03) 43.9* (11.5) 6.3* (0.5) 47.8* (11.7)
Warfarin (n = 3)
Native serum 1.6 (0.4) 1.3 (0.1) 1.2 (0.02) 1.0 (0.2) 10.4 (3.4) 20.3 (2.9) 9.4 (0.9) 18.1 (3.2)
Sigma albumin 1.6 (0.2) 1.4 (0.3) 1.4 (0.2) 1.6 (0.1) 11.4 (2.1) 30.9 (7.0) 13.5 (3.1) 47.6 (3.6)
Digitoxin (n = 3)
Native serum 1.6 (0.2) 1.4 (0.4) 1.4 (0.5) 1.2 (0.3) 54.2 (8.1) 68.6 (23.2) 50.1 (28.4) 63.4 (28.4)
Sigma albumin 1.3 (0.1) 1.2 (0.1) 1.0 (0.3) 1.0 (0.2) 41.0 (11.0) 66.8 (14.7) 28.3 (18.3) 57.2 (32.3)
The effects of the stabilisers caprylate (C) and N-acetyl-DL-tryptophan (T) and both (C+T) on naproxen, warfarin, and digitoxin binding were 
tested with ultrafiltration of human serum and Sigma albumin after addition of the stabilisers and ligands. The results were calculated according to 
Scatchard [17] and expressed by specific binding sites (n1) and dissociation constants (K1). The final concentrations of caprylate and N-acetyl-DL-
tryptophan were each 3.2 and 3.3 mmol/L respectively. The values are means (SDs) of 5 separate experiments with naproxen and 3 with warfarin 
and digitoxin. *p < 0.05 compared with no stabiliser (No).BMC Clinical Pharmacology 2004, 4 http://www.biomedcentral.com/1472-6904/4/4
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Lineweaver-Burk plots of naproxen (a), warfarin (b) and digitoxin (c) binding in various albumin solutions Figure 2
Lineweaver-Burk plots of naproxen (a), warfarin (b) and digitoxin (c) binding in various albumin solutions 
Lineweaver-Burk plots of naproxen (a), warfarin (b) and digitoxin (c) binding in various albumin solutions. The figures are based 
on the results representing the specific binding, presented in total in table 2 and figure 1.
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ceutical-grade albumin (Table 2 and 3) with the methods
we have used, whereas for warfarin and digitoxin the dis-
sociation constant only increased.
Thus, displacement effects of the stabilisers are most
likely. If the findings of Børmer et.al. and the present
results reflect changed binding capacity of albumin also in
vivo, it raises the possibility that altered albumin binding
may contribute to the possible detrimental effect of albu-
min transfusions. Patients with either hypoalbuminaemia
or patients receiving large amounts of pharmaceutical-
grade albumin might be at special risk, as discussed
recently in a meta-analysis that demonstrated no overall
effect of albumin transfusion on mortality [5]. The report
from the Cochrane injuries group albumin reviewers [4]
indicated possible harmful effects and excess mortality
after albumin administration to critically ill patients.
However, the validity of the Cochrane meta-analysis has
been challenged by a recent meta-analysis [5]. Naproxen,
warfarin, and digitoxin are drugs used in post-operative
and intensive care units. Increased free fraction of such
drugs may cause enhanced adverse effects and possibly
serious adverse effects. Thus, it could be hypothesised that
the combination of transfusing large amounts of pharma-
ceutical-grade albumin solutions and certain highly albu-
min-bound drugs might precipitate detrimental effects in
critically ill patients. However, further in vitro and in vivo
studies will be needed to examine if these results can have
consequences for patients receiving large amounts of
pharmaceutical-grade albumin and certain highly albu-
min-bound drugs.
Conclusions
Previous studies have indicated that transfusion of phar-
maceutical-grade albumin to critically ill patients is con-
troversial. The present in vitro studies of drug binding
capacity of pharmaceutical-grade albumin demonstrate
that the specific binding of naproxen is no longer detecta-
ble and the specific binding of warfarin and digitoxin is
significantly reduced. The studies further shows that
caprylic acid and N-acetyl-DL-tryptophan, used as stabilis-
ers in the purification process when manufacturing phar-
maceutical albumin, are of importance of this effect, and
that the impairing or displacing effect might be of com-
petitive nature.
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Table 4: Effects of charcoal-treatment on naproxen, warfarin, and digitoxin binding in albumin solutions with/without stabilisers#
Not charcoal treated albumin Charcoal treated albumin
In-process Final product In-process Final product
Naproxen
K1 (µmol/L) 0.1* (0.01) 75.5 (3.9) 0.2 (0.02) 0.2 (0.02)
n1 0.9* (0.2) 5.7 (0.3) 0.9 (0.1) 1.1 (0.1)
Warfarin
K1 (µmol/L) 13.1* (1.6) 43.1 (7.1) 13.5 (0.6) 14.6 (2.4)
n1 1.9 (0.2) 1.7 (0.2) 1.7 (0.1) 2.0 (0.2)
Digitoxin
K1 (µmol/L) 19.7* (1.0) 67.6 (6.8) 20.8 (1.0) 31.0 (4.2)
n1 0.8 (0.03) 1.1 (0.1) 0.8 (0.03) 1.3 (0.2)
Effects of charcoal treatment on naproxen, warfarin, and digitoxin binding in two different albumin solutions. The in-process albumin solution 
(collected from the albumin manufacturing process before addition of the stabilisers and final heating) and the final product. Values are means (SDs) 
of 5 separate experiments. #: The concentration of N-acetyl-DL-tryptophan was 3 mmol/L in the final product before charcoal treatment, but not 
detectable (<0.2 µmol/L) after charcoal treatment (separate analysis). *p < 0.05 compared with the final product not charcoal treated.Publish with BioMed Central    and   every 
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